Pfizer Inc PFE

$27.40 -0.14 (-0.51%)

Valuation

Market cap
156,973,984,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.20
P/E (forward)
9.22
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
38,319,626
Avg volume
34,049,391
Day's range
$27.35 – $28.11
Shares out
5,699,854,000
Stochastic %K
2%
Beta
0.31
Analysts
Hold
Price target
$30.56

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

truthseeeker Nov 21, 3:15 PM
$PFE EXTREMISTS who make ridiculous predictions that ACTUALLY ALWAYS FAIL TO HAPPEN, dominate the posting. Nov 19, one made the prediction PFE would go to $21 by Xmas. While it is true that since trading at the silly high price of $31 plus on the day before the recent Nov 5 ex dividend date stock has predictably sold off ( I posted that it would) & that the down has been added to by FED threatening interest rate hikes, that as stock price goes down dividend rate rises which has always supported the stock. At yesterday's close the dividend rate is 6.27%. The 200 day average which should provide some decent support is at $27.03 . If that breaks and the stock moves to $26, the dividend rate rises to 6.615 %, at $25 the rate is 6.88% , a little lower it is 7% which would provide TREMENDOUS support, so $21 , especially in one month is ABSURD, just as ABSURD as the prediction for $35 we saw a few weeks ago. NEITHER WILL HAPPEN!
0 replies
GooRich Nov 21, 1:59 PM 0 replies
PB09 Nov 21, 8:53 AM
Here is some Hopium $CAPR — still see a possible path here. * HOPE-3 published in The Lancet * Trial doctors publicly backed approval * Patient/family testimony at AdCom * Eliquis ($BMY/$PFE), Ryoncil ($MESO), Vyondys 53 ($SRPT): CRLs → eventual approvals FDA says HOPE-3’s data issues can’t be fixed after the fact. Serious hurdle. Tell them What actually happened, using original records. The scope and timing of any loss of blinding. Who had access to treatment information when analytical changes were made. Whether an acceptable analysis of reliable data still supports efficacy. Whether FDA agrees that the problems have been adequately bounded. Still believe eventual approval is possible if CAPR can establish a path FDA will accept.
1 replies
openclassaction2 Nov 21, 4:33 AM
$PFE the $44 million pfizer chantix settlement is pending approval, per open class actions. suit alleged chantix had an undisclosed nitrosamine impurity. drug safety, settled before trial
0 replies
Akindawager Nov 20, 9:04 PM
$PFE I sold MU at $826, MSFT at $550, NVDA at $155. My timing has been freakishly good for a minute…welp I bought into PFE at $27.60…/fingers crossed i figured people will want to park their money somewhere…pfe barely moves and has nice div…why not here?
3 replies
PFElinepfrenzy1990 Nov 20, 9:01 PM
$PFE - Not bad, considering. Well done, my darling shitco 🥰
1 replies
STOCKPICKERTRADER Nov 20, 7:27 PM
$PFE so this is what an upgrade to BUY feels like... Jefferson Research upgrades Pfizer from HOLD to BUY. INVESTARS ANALYST ACTIONS - PUBLIC Nov-19-2026 12:22 p.m. ET On November 19, 2026 Jefferson Research upgraded Pfizer (PFE) from HOLD to BUY.
3 replies
bossgangvip Nov 20, 6:21 PM
$PFE Defense low beta Thanksgiving week. 🙏🏿
0 replies